Recently, Sawada et al. have analyzed c-MET role in ovarian cancer biology and its possible implication as a therapeutic target; so, it has been established the c-MET over-expression, especially in patients in higher stage disease [36]. This evidence concerns the gene MET and ovarian carcinoma.